For instance, anti-vascular endothelial growth factor (VEGF) treatment with a specific monoclonal antibody (Bevacizumab) is beneficial in breast cancer when added to neoadjuvant chemotherapy but detrimental in an adjuvant setting [5,6]. This evidence concerns the gene VEGFA and breast carcinoma.